Letters by company
Zedcor Inc.
2 letters discussing ZDCAF. Everything written about it on this site is on its ticker page.
- Cedar Grove Capital Management Q3’2026 Cedar Grove increased gross leverage and added Zedcor, OneSpaWorld and Auxly while closing several special-situation and biotech holdings. The portfolio argues that Evolv Technologies and The RealReal retain improving operating fundamentals despite rate-driven valuation pressure, with recurring revenue and marketplace efficiency as the central theses. Q3 2026 EVLV $709MABVX $7.1BAXON $26B
- Donville Kent Asset Management Inc. The Case for Fundamentals Donville Kent argues that earnings compounding and valuation discipline offer diversification from crowded AI-linked momentum trades. It discusses Blue Ant’s post-transaction earnings potential, VitalHub’s AI-enabled healthcare software, Zedcor’s internally developed monitoring platform, and the operating growth across several portfolio companies. July 2026 BAMI $105MCIFR $3BETOLF $80M